Posts by: David Melamed, PhD

David Melamed, PhD

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

October 9, 2020October 9, 2020

First Patient Dosed in Pivotal AFFINE Study of Potential Gene Therapy SB-525

News

The first participant was dosed with the investigational gene therapy treatment SB-525 (giroctocogene fitelparvovec) in a Phase 3 clinical trial in men with hemophilia A, according to developers Pfizer and ... Read more

August 7, 2020August 7, 2020

Long-term Adynovate Therapy Reduces Bleeding in Severe Hemophilia A

News

Long-term prophylaxis, or preventive treatment with Adynovate continues to safely reduce bleeding events over multiple years in children and adults with severe hemophilia A without causing neutralizing antibodies, a Phase ... Read more

March 27, 2020March 27, 2020

Phase 3 Trial of AMT-061 Gene Therapy for Hemophilia B Exceeds Target Dosing

News

A Phase 3 clinical trial investigating gene therapy candidate AMT-061 (etranacogene dezaparvovec) has reached its target of dosing 50 participants with moderate or severe hemophilia B. In fact, according to ... Read more

March 2, 2020March 2, 2020

Low Doses of EHL-FIX Concentrates Can Prevent Bleeds in Severe Hemophilia B, Study Finds

News

When given at low doses, extended half-life factor IX concentrates Alprolix (eftrenonacog alfa) and Idelvion (albutrepenonacog alfa) can prevent spontaneous bleeds in patients with severe hemophilia B, a study has ... Read more